InMode INMD shares are trading higher after the company reported better-than-expected second-quarter EPS and sales results. The company also issued fiscal year 2020 sales guidance above analyst estimates.
InMode is a provider of minimally-invasive surgical aesthetic and medical treatment solutions in the United States. Its products and solutions are designed to address three energy-based treatment categories including face and body contouring, medical aesthetics and women's health. The technologies offered by the company include BodyTite, Contoura, EmbraceRF, Optimas, and Votiva among others.
InMode shares were trading at $35.23 but have since fallen to $32.57 at time of publication on Wednesday. The stock has a 52-week high of $58.76 and a 52-week low of $13.06.
Related Link:
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
